Registered title, quoted from ClinicalTrials.gov
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06437509, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Newly diagnosed patients with extensive-stage small cell lung cancer confirmed by histopathology and / or cytology;
Inclusion criterion 5
The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
Inclusion criterion 9
ECOG score 0-1;
Inclusion criterion 4
No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;
Inclusion criterion 8
At least one measurable lesion meeting the RECIST v1.1 definition was required;
Inclusion criterion 7
Other malignancies that have progressed or require treatment within 5 years prior to the first dose;
Exclusion criterion 9
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06437509, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Subject volunteered to participate in the study and signed an informed consent;
- Male or female aged ≥18 years and ≤75 years;
- Expected survival time ≥3 months;
- ECOG score 0-1;
- Newly diagnosed patients with extensive-stage small cell lung cancer confirmed by histopathology and / or cytology;
- A archived tumor tissue sample or fresh tissue sample of the primary or metastatic lesion must be provided within 3 years;
- At least one measurable lesion meeting the RECIST v1.1 definition was required;
- No blood transfusion and no use of cell growth factors and/or platelet-raising drugs within 14 days before screening, and the organ function level must meet the requirements;
- The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, a serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Prior use of ADC drug therapy with small molecule toxins as topoisomerase I inhibitors;
- Prior treatment with any systemic anti-tumor regimen for extensive-stage small cell lung cancer;
- Pathology suggested small cell carcinoma containing non-small cell carcinoma components;
- Subjects had used immunomodulatory drugs within 14 days before the first use of the study drug ;
- Screening the history of severe cardiovascular and cerebrovascular diseases in the first half of the year ;
- QT interval prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia ;
- Active autoimmune diseases and inflammatory diseases ;
- Receiving long-term systemic corticosteroid therapy or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy prior to the first dose;
- Other malignancies that have progressed or require treatment within 5 years prior to the first dose;
- Have ILD requiring steroid therapy, or currently have ILD, or suspected ILD at screening;
- Prior to initiation of study treatment, there were: a) poorly controlled diabetes mellitus; b) with severe complications of diabetes; c) glycosylated hemoglobin levels of 8% or more; d) hypertension that is poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;
- Unstable thrombotic events requiring therapeutic intervention within 6 months prior to screening; Except for infusion set-related thrombosis;
- Concurrent pulmonary disease leading to severe clinical impairment of respiratory function;
- Patients with active central nervous system metastases;
- Patients with large serosal effusions, or symptomatic serosal effusions, or poorly controlled serosal effusions;
- History of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipient component of the experimental drug;
- Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
- Severe infection within 4 weeks prior to first dose of study drug; Lung infection or active lung inflammation within 4 weeks;
- Have participated in another clinical trial within 4 weeks prior to the first dose;
- Have a history of psychotropic substance abuse and cannot be abstained from or have a history of severe neurological or psychiatric disorders;
- Imaging examination showed that the tumor had invaded or encapsulated the large blood vessels in the chest;
- Severe and non-healing wounds, ulcers, or fractures within 4 weeks prior to signing the informed policy;
- Clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing the informed policy;
- Subjects who are scheduled to receive or receive a live vaccine within 28 days prior to the first dose;
- Other conditions that the investigator considers unsuitable to participate in this clinical trial.
Quoted from ClinicalTrials.gov, NCT06437509, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06437509, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.